Pfizer Inc.

Overview

Pfizer Inc. (PFE)

  • Exchange: NYSE
  • Current Share Price: $26.70
  • Change: +$0.44 (1.68%)

Notable Price Movement

After Hours

  • Date: Apr 30
  • Price: $26.70 (1.68% at Close)
  • After Hours Price: $26.68 (0.07% After Hours)

Pfizer rose nearly 2% on April 30, buoyed by a confluence of positive catalysts. Earlier in the week, the company announced patent settlements for its ATTR-CM drug Vyndamax with three generic manufacturers, extending U.S. exclusivity to mid-2031 and stabilizing revenue expectations from 2028 onward. Additionally, Pfizer reported positive Phase 3 results for ELREXFIO in relapsed/refractory multiple myeloma, showing statistically significant improvement in progression-free survival versus standard of care. These developments come ahead of Pfizer's May 5 earnings report, with analyst consensus holding a Hold rating and an average price target of $29.42, while some valuation models suggest meaningful upside from current levels.

Price Change History

Date Closing Price Change
Apr 29 $26.27 -0.79%
Apr 28 $26.48 -1.18%
Apr 27 $26.81 -0.70%
Apr 24 $26.98 +1.16%
Apr 23 $26.66 -0.53%
Apr 22 $26.78 -1.94%
Apr 21 $27.31 -0.76%
Apr 20 $27.52 +0.15%
Apr 19 $27.56 +1.25%
Apr 18 $27.21 +0.07%
Apr 17 $27.32 +1.49%
Apr 16 $27.13 +0.77%
Apr 15 $27.19 +0.30%

Analyst Consensus

Consensus: Hold

  • Bearish: 1
  • Neutral: 5
  • Bullish: 3
  • Price Targets:
    • Low: $25
    • Current: $26.70
    • Average: $29
    • High: $36

Key Issues

Valuation

  • Bullish View: Pfizers discounted cash flow analysis suggests shares are approximately 59% below estimated intrinsic value of ~$64.92.
  • Bearish View: GuruFocus's GF Value model indicates Pfizer's intrinsic value at $25.53, suggesting current stock prices might be overvalued.

Additional Information

  • Symbol: PFE
  • IPO Date: May 31, 1972
  • CEO: Albert Bourla
  • Fulltime Employees: 81K
  • Country: United States
  • Sector: Healthcare
  • Industry: Drug Manufacturers - General